Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclax

3 Aug 2023

Abstract excerpt

Despite recent advances in the therapy of diffuse large B-cell lymphoma (DLBCL), many patients are still not cured. Therefore, new therapeutic strategies are needed. The anti-apoptotic B-cell lymphoma 2 (BCL2) gene is commonly dysregulated in DLBCL due to various mechanisms such as chromosomal translocation t(14;18)(q32;q21) and copy number alterations; however, targeting BCL-2 with the selective inhibitor,...

Source

Identifiers

PMID: 37534528
DOI: 10.3324/haematol.2023.283245

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclaxPMID 37534528Read ↗

Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignanciesSemantic proximity Read ↗

Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell LymphomasSemantic proximity Read ↗

Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypesSemantic proximity Read ↗

Mitochondrial apoptosis and BH3 mimeticsSemantic proximity Read ↗

Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistanceSemantic proximity Read ↗

SETD1B mutations confer apoptosis resistance and BCL2 independence in B cell lymphoma.Semantic proximity Read ↗

CS2164 and Venetoclax Show Synergistic Antitumoral Activities in High Grade B-Cell Lymphomas With MYC and BCL2 RearrangementsSemantic proximity Read ↗

BCL2-Family Dysregulation in B-Cell Malignancies: From Gene Expression Regulation to a Targeted Therapy BiomarkerSemantic proximity Read ↗

Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target ResistanceSemantic proximity Read ↗

The potential of venetoclax (ABT-199) in chronic lymphocytic leukemiaSemantic proximity Read ↗

BCL-2 Proteins in Pathogenesis and Therapy of B-Cell Non-Hodgkin LymphomasSemantic proximity Read ↗

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid MalignanciesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.